Sign In
Buy TPST
$0.95
-0.0136 (-1.41%)
At Close: Jul 20, 2026
Top trending biotech stocks: ANVS, MTNB, AVTX, TPST
11:26am, Thursday, 12'th Oct 2023
Biotech stocks are some of the most volatile in the market because of the regular FDA updates and mergers and acquisitions in the industry. Some of the most notable M&A events this year were Pfizer's
TPST Stock: 7 Things to Know About Tempest Therapeutics
04:29pm, Wednesday, 11'th Oct 2023
Today, most of Wall Street is watching Tempest Therapeutics (NASDAQ: TPST ). This little-known clinical-stage oncology company has gone from trading at 30 cents per share 24 hours ago to its current s
Wall Street Warms Up to Tempest as TPST Stock Surges 1,500%
12:54pm, Wednesday, 11'th Oct 2023
Tempest Therapeutics (NASDAQ: TPST ) is the stock to watch for today, as its shares are up by a staggering 1,500%. This morning, the cancer therapies company reported positive results for its TPST-112
Tempest Therapeutics' stock jumps 1,900% as liver-cancer treatment shows promise
12:29pm, Wednesday, 11'th Oct 2023
Shares of Tempest Therapeutics Inc. TPST, +1942.52% soared more than 1,900% on Wednesday after the company released study results for its investigational cancer treatment TPST-1120 in patients with li
Why Is Tempest Therapeutics (TPST) Stock Up 325% Today?
07:41am, Wednesday, 11'th Oct 2023
Tempest Therapeutics (NASDAQ: TPST ) stock is taking off on Wednesday as the clinical-stage oncology company prepares to release new study results. According to a press release from the company, it i
Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
04:05pm, Tuesday, 10'th Oct 2023
Webcasted Conference Call on Wednesday, October 11, 2023 at 8:30 a.m. ET Webcasted Conference Call on Wednesday, October 11, 2023 at 8:30 a.m. ET
All You Need to Know About Tempest Therapeutics, Inc. (TPST) Rating Upgrade to Buy
05:42pm, Tuesday, 15'th Aug 2023
Tempest Therapeutics, Inc. (TPST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Tempest to Present at the Jefferies Global Healthcare Conference
04:05pm, Wednesday, 31'st May 2023
BRISBANE, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and i
Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers
05:00pm, Thursday, 25'th May 2023
• Data show tumor shrinkage and prolonged disease control in both monotherapy and in combination with pembrolizumab • Oral, once-daily cancer treatment well tolerated with a manageable safety prof
Tempest Therapeutics, Inc. (TPST) Upgraded to Buy: What Does It Mean for the Stock?
01:42pm, Monday, 01'st May 2023
Tempest Therapeutics, Inc. (TPST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
04:58pm, Thursday, 27'th Apr 2023
BRISBANE, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and
Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting
04:30pm, Tuesday, 14'th Mar 2023
BRISBANE, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and
Tempest to Present at the Piper Sandler 34th Annual Healthcare Conference
04:05pm, Tuesday, 22'nd Nov 2022
SOUTH SAN FRANCISCO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company focused on developing first-in-class therapeutics that combi
Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit
08:00am, Thursday, 06'th Oct 2022
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both ta
Tempest to Present at the Jefferies Healthcare Conference
04:05pm, Monday, 06'th Jun 2022
SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both ta
